Chinese biotech developing antiviral drugs (hepatitis, HIV) and newer obesity/metabolic and oncology drug candidates.
Chinese biotech developing antiviral drugs (hepatitis, HIV) and newer obesity/metabolic and oncology drug candidates.
Income so far is small next to development spending, which is funded by investor money and out-licensing deals. Success rests on its obesity candidates reaching late-stage trials.
Moat: narrow (IP / patents). First-mover China antiviral approvals and a differentiated oral obesity pipeline, still early-stage overall.
Headquarters: Hangzhou, China · Founded: 2013 · Employees: 202
Size Ascletis Pharma (1672.HK) is a Hong Kong Health Care company (Biotechnology) with a market value of $571M, the 717th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$4.37 on 18 Nov 2026.
Performance Over six months the shares fell 71.8%, against -17.1% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — lowest of 19 in its peer set.
Growth Revenue fell 59.4% over the last twelve months (peer median +9.1%); the operating margin is -71,976.2% (peer median -10.7%).
Valuation It trades at 1,794.8× enterprise value to sales against a peer median of 3.4× (most expensive of 16).
Next results Next results expected around 30 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$1.04M | HK$2.20M | HK$1.39M | HK$62.5M | HK$62.9M |
| Revenue growth | — | +58% | -98% | -1% | — |
| Gross profit | -HK$18.3M | -HK$18.5M | -HK$21.7M | HK$7.97M | -HK$58.3M |
| EBITDA | -HK$727M | -HK$506M | -HK$415M | -HK$320M | -HK$365M |
| Net income | -HK$662M | -HK$390M | -HK$326M | -HK$160M | -HK$366M |
| Free cash flow | -HK$566M | -HK$368M | -HK$239M | -HK$166M | -HK$174M |
| Capital expenditure | HK$2.48M | HK$2.14M | HK$2.33M | HK$21.2M | HK$16.7M |
| Total debt | n/a | HK$5.75M | HK$8.12M | HK$9.27M | HK$4.76M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Ascletis Pharma 1672.HK | $571M | -72% | -59% | -71,976% | 1,794.8× | n/a |
| Innovent Biologics 1801.HK | $18.9B | +4% | +43% | 17% | 7.3× | 11.6% |
| Jiangsu Hengrui Pharmaceuticals 600276.SS | $45.7B | -13% | +6% | 27% | 8.0× | 13.4% |
| Lilly (Eli) LLY | $1.30T | +36% | +46% | 51% | 15.6× | 6.5% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 1672.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -23.7% | -12.2% | 3rd lowest of 21 |
| 6-month return | -71.8% | -17.1% | lowest of 19 |
| Distance from 52-week high | -78.0% | -49.8% | 2nd lowest of 21 |
| Revenue growth (TTM) | -59.4% | +9.1% | lowest of 17 |
| Operating margin | -71,976.2% | -10.7% | lowest of 17 |
| EV / Sales | 1,794.8× | 3.4× | most expensive of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Ascletis Pharma 1672.HK | Hong Kong | $571M | -72% | -59% | -71,976% | 1,794.8× | n/a | n/a |
| Genfit GNFT.PA | France | $571M | +22% | +28% | -130% | 11.0× | 39.8% | +143.5% |
| 4D Molecular Therapeutics FDMT | United States | $578M | +23% | +79,952% | -226% | 3.2× | n/a | n/a |
| Boji Medical Technology 300404.SZ | China | $561M | -6% | +32% | 4% | 3.4× | 31.9% | +27.2% |
| Sana Biotechnology SANA | United States | $554M | -41% | n/a | n/a | n/a | n/a | n/a |
| Hvsen Biotechnology 300871.SZ | China | $553M | -22% | +2% | 17% | 2.3× | n/a | n/a |
| Alebund Pharmaceuticals (Jiangsu) 9637.HK | Hong Kong | $595M | n/a | +674% | -495% | 26.8× | n/a | n/a |
| Wave Life Sciences WVE | United States | $546M | -55% | -35% | -321% | 2.2× | n/a | n/a |
| Climb Bio CLYM | United States | $546M | -12% | n/a | n/a | n/a | n/a | n/a |
| Frontage 1521.HK | Hong Kong | $542M | +113% | +10% | 8% | 2.3× | 14.3% | +15.4% |
| Anhui Huaheng Biotechnology 688639.SS | China | $605M | -45% | +7% | 3% | 1.9× | n/a | n/a |
| Surrozen SRZN | United States | $605M | +17% | +192% | -485% | 48.5× | n/a | n/a |
| Design Therapeutics DSGN | United States | $606M | -15% | n/a | n/a | n/a | n/a | n/a |
| Getein Biotech 603387.SS | China | $625M | -13% | +8% | 21% | 2.6× | -8.9% | -1.3% |
| Beijing Bohui Innovation Biotechnology 300318.SZ | China | $518M | -20% | -1% | -13% | 6.2× | n/a | n/a |
| Janux Therapeutics JANX | United States | $631M | -28% | +133% | -599% | n/a | n/a | n/a |
| Shenzhen Weiguang Biological Products 002880.SZ | China | $633M | -27% | 0% | 18% | 4.4× | n/a | n/a |
| LongBio Pharma (Suzhou) 1779.HK | Hong Kong | $510M | n/a | n/a | n/a | n/a | n/a | n/a |
| Geron GERN | United States | $638M | -21% | +19% | -8% | 2.8× | n/a | n/a |
| Valneva VLA.PA | France | $508M | -6% | -27% | -87% | 3.9× | n/a | n/a |
| Beijing Scitop Bio-Tech 300858.SZ | China | $501M | -28% | +4% | 8% | 7.5× | n/a | n/a |